NCT02089594 is a Phase 3 clinical trial of Hyperbaric Oxygen in Post-Concussion Syndrome, sponsored by Louisiana State University Health Sciences Center in New Orleans.

Who is sponsoring NCT02089594?

NCT02089594 is sponsored by Louisiana State University Health Sciences Center in New Orleans.

What drugs are being tested in NCT02089594?

Interventions in NCT02089594: Hyperbaric Oxygen, No Hyperbaric Oxygen.

What condition does NCT02089594 study?

NCT02089594 studies Post-Concussion Syndrome, Traumatic Brain Injury.

Is NCT02089594 still recruiting?

NCT02089594 is currently status unknown. Last updated 16 April 2017.

Last reviewed 2017-04-16 · How we verify

NCT02089594

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyperbaric Oxygen Therapy Treatment of Chronic Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS)

Status unknown Phase 3 Last updated 16 April 2017

What this trial tests

Phase 3 trial testing Hyperbaric Oxygen in Post-Concussion Syndrome in 59 participants. Status unknown.

Timeline

1 May 2014

Primary endpoint
1 March 2018

1 March 2019

Quick facts

Lead sponsor	Louisiana State University Health Sciences Center in New Orleans
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	59
Start date	1 May 2014
Primary completion	1 March 2018
Estimated completion	1 March 2019
Sites	1 location across United States

Drugs / interventions tested

Hyperbaric Oxygen — full drug profile →
No Hyperbaric Oxygen — full drug profile →

Conditions studied

Post-Concussion Syndrome — all drugs for Post-Concussion Syndrome →
Traumatic Brain Injury — all drugs for Traumatic Brain Injury →

Sponsor

Louisiana State University Health Sciences Center in New Orleans

Who can join

Adults 18 to 65, any sex, with Post-Concussion Syndrome or Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Working Memory
Time frame: One week after final HBOT
Neurobehavioral Symptom Inventory (NSI)
Time frame: One week after final HBOT

Sponsor's own description

Objective/Hypothesis: An eight-week course of forty low-pressure Hyperbaric Oxygen Treatment's (HBOT's) can significantly improve symptoms and cognitive function in subjects with the persistent-post concussion syndrome (PPCS) of mild traumatic brain injury (mTBI).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Hyperbaric oxygen therapy for mild traumatic brain injury persistent postconcussion syndrome: a randomized controlled trial.
Harch PG, Andrews SR, Rowe CJ, Lischka JR, et al · · 2020 · cited 39× · PMID 32189664 · DOI 10.4103/2045-9912.279978
Detrimental Roles of Hypoxia-Inducible Factor-1α in Severe Hypoxic Brain Diseases.
Choi YK. · · 2024 · cited 23× · PMID 38674050 · DOI 10.3390/ijms25084465
Hyperbaric oxygen therapy as a potential treatment for post-traumatic stress disorder associated with traumatic brain injury.
Eve DJ, Steele MR, Sanberg PR, Borlongan CV. · · 2016 · cited 21× · PMID 27799776 · DOI 10.2147/ndt.s110126
Traumatic brain injury and immunological outcomes: the double-edged killer.
Datta S, Lin F, Jones LD, Pingle SC, et al · · 2023 · cited 10× · PMID 37228857 · DOI 10.2144/fsoa-2023-0037

Verify or expand the search:

Other trials of Hyperbaric Oxygen

Trials testing the same drug.

NCT04664790 — Hyperbaric Oxygen Therapy Compared to Cognitive Training in FASD · NA · not yet recruiting
NCT04717557 — Hyperbaric Oxygen and Outcome After Below Knee Amputations · Phase 1, PHASE2 · terminated
NCT04477954 — Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia · Phase 2 · terminated
NCT01986205 — Hyperbaric Oxygen for Traumatic and Non-traumatic Brain Injury · Phase 2 · completed
NCT02984943 — The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis · NA · completed

Other Louisiana State University Health Sciences Center in New Orleans trials

Trials by the same sponsor.

NCT07462767 — Precision Microbiota Interventions for Senoreduction Trial · Phase 1, PHASE2 · not yet recruiting
NCT07488156 — Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder · NA · not yet recruiting
NCT07280260 — Clinical Performance of Nobel N1 System · Phase 4 · recruiting
NCT06773715 — Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain · NA · recruiting
NCT06874244 — Clinical Evaluation of no Needle Dental Anesthesia Compared to Syringe Anesthesia Delivery · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02089594 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Louisiana State University Health Sciences Center in New Orleans
Last refreshed: 16 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02089594.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing